Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.530% | 3.977% | -1.613% | 14.375% | 10.241% | 4.571% | -60.432% |
| Northwest Biotherapeutics Inc. | 0.000% | 38.462% | 12.500% | -18.919% | -12.621% | -59.641% | -81.053% |
| Achieve Life Sciences Inc. | -1.720% | 4.505% | 13.725% | 180.193% | 56.757% | 20.833% | -10.769% |
News
Lumexa Imaging Q2 Earnings Call Highlights
Key Points
- Interested in Lumexa Imaging Holdings, Inc.? Here are five stocks we like better.
- Lumexa returned to profitability in Q2: Revenue rose 5.1% year over year to $264.2 million, net
Advanced Micro Devices vs. AppLovin: Which Technology Stock Is a Better Buy in 2026?
Investors face a choice between hardware and software dominance as Advanced Micro Devices (NASDAQ:AMD) and AppLovin (NASDAQ:APP) compete for capital in an increasingly artificial intelligence-driven
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Key Points
- Interested in Candel Therapeutics, Inc.? Here are five stocks we like better.
- Candel Therapeutics plans to submit a biologics license application by the end of 2026 for aglatimagene